Publication in refereed journal
香港中文大学研究人员 ( 现职)
| 陶谦教授 (肿瘤学系) |
全文
| 数位物件识别号 (DOI) http://dx.doi.org/10.1016/j.canlet.2006.08.019 |
引用次数
Web of Sciencehttp://aims.cuhk.edu.hk/converis/portal/Publication/29WOS source URL
其它资讯
摘要Epigenetic mechanisms involving DNA methylation and chromatin remodeling are important in silencing tumor suppressor genes (TSG) in various malignancies, including renal cell carcinoma (RCC). DLC1 (deleted in liver cancer 1)/ARHGAP7 is a recently identified 8p22 candidate TSG. Frequent methylation of the DLC1 promoter with resultant gene silencing has been reported in several tumors, but not in RCC yet. We examined DLC1 promoter methylation in 34 primary RCCs and the corresponding non-malignant tissues, and the correlation of DLC1 methylation with the clinicopathological characteristics of RCC patients. Although DLC1 methylation and downregulation were only detected in one of seven RCC cell lines using methylation-specific PCR (MSP) and semi-quantitative reverse-transcription PCR, we found that the DLC1 promoter was methylated in 35% (12/34) of primary RCC tumors, which was further confirmed by direct sequencing of MSP products and high-resolution bisulfite genomic sequencing. In contrast, only one of the 34 (3%) non-malignant renal tissues had weak methylation. Aberrant DLC1 methylation appeared to be a relatively early event during renal tumorigenesis since 33% of the RCC tumors with pT1 (TNM staging) showed methylation, which is similar to other late stage tumors. Thus, our results demonstrated that DLC1 methylation occurs in a subset of RCC tumors and may play a role in renal carcinogenesis. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
着者Zhang Q, Ying JM, Zhang K, Li HY, Ng KM, Zhao YY, He Q, Yang XY, Xin DQ, Liao SK, Tao Q, Jin J
期刊名称Cancer Letters
出版年份2007
月份5
日期8
卷号249
期次2
出版社ELSEVIER IRELAND LTD
页次220 - 226
国际标準期刊号0304-3835
电子国际标準期刊号1872-7980
语言英式英语
关键词carcinoma; DLC1 gene; methylation; renal; tumor suppressor gene
Web of Science 学科类别Oncology; ONCOLOGY
